fda drug safety communication semaglutide naion 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" FDA-Approved Obesity Medications Timeline: Evolution

This guide explains how it works, its potential health benefits, and recommended usage.

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs

Key features include: Persistent right upper quadrant pain lasting more than six hours Fever and systemic signs of infection Tenderness in the right upper abdomen that worsens during deep breathing Jaundice (yellowing of skin and eyes) if bile duct obstruction occurs Dark urine and pale stools Loss of appetite and general malaise Some patients may experience chronic cholecystitis , characterised by recurrent episodes of milder abdominal discomfort, bloating, and intolerance to fatty foods

GLP-1 RAs, CARDIOVASCULAR AND RENAL PROTECTION IN PATIENTS WITH T2DM The case for additional RAAS blockade in diabetic kidney disease RAAS blockade is a pillar of DKD management, with benefits demonstrated in clinical trials for both primary and secondary prevention [8286]

2023 Sep 7;389(10):877-888

Macrophage fatty acid oxidation in atherosclerosis